FIDEC was honored with the 2024 Innovating for Impact Partnership Award from the Global Health Technologies Coalition (GHTC) in recognition of its contribution to the research and development of the novel oral polio vaccine type 2 (nOPV2).
Developed through a global partnership led by PATH, nOPV2 became the first vaccine authorized by the WHO for emergency use and has since helped reduce outbreaks of circulating vaccinederived poliovirus type 2, with more than one billion doses delivered worldwide.